Drug intelligence / Profile preview

RG54

Development stage: Preclinical
Modality: Peptides

Overview

RG54 is a short peptide sequence derived from apolipoprotein A-I (ApoA-I). It has demonstrated the ability to increase glucose tolerance and prevent the formation of atherosclerosis in mice. The drug's therapeutic potential is being explored for individuals with diabetes, particularly those with severe insulin resistance, by improving glucose uptake in skeletal muscle independently of insulin levels and signaling.

Targets

RDM1 (RAD52 motif-containing protein 1)SCARB1 (Scavenger receptor class B member 1)ABCA1 (ATP-binding cassette transporter A1)

Beyond the preview

Go deeper on RG54.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG54.

Explore the full profile